drugset / Trial / NCT03699202
Anti-RSV Study in Chinese Patients (ASCENT)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.
Timeline
- Start
- 2019-03-28
- Primary completion
- 2019-04-04
- Completion
- 2019-04-04
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated early due to COVID-19-related enrollment disruptions, not as a result of any product safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziresovir | Small molecule | 100 mg | Oral |
| Subject | Ziresovir | Small molecule | 200 mg | Oral |
| Subject | Ziresovir | Small molecule | 300 mg | Oral |